Treatment outcomes in a cohort of patients with mucosal-predominant pemphigus vulgaris

摘要

BackgroundPemphigus vulgaris (PV) is a rare autoimmune blistering condition. Treatment typically combines corticosteroids with another immunosuppressive agent, such as azathioprine, mycophenolate mofetil (MMF) or rituximab.